COMMUNIQUÉS West-GlobeNewswire

Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®
07/09/2026
Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio ® BREATHE prévoit d’implanter jusqu’à 229 patients dans jusqu’à 25 centres américains, suivis pendant [...]
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
07/09/2026
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio ® System BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed for up to five years, to [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
07/09/2026
Déclaration de transactions sur actions propres Paris, France (7 septembre 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 28 avril 2026, EssilorLuxottica déclare que du 31 août 2026 au [...]
EssilorLuxottica: Disclosure of transactions in own shares
07/09/2026
Disclosure of transactions in own shares Paris, France (September 7, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 28, 2026, EssilorLuxottica declares that [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
07/09/2026
Nantes, le 7 septembre 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 36 - 2025
07/09/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 31 août au 4 septembre 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2025
07/09/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 31st August to 04th September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial [...]
Peptides Canada Reports Growing Research Demand for Retatrutide Amid Expansion of Domestic Peptide Supply Market
07/09/2026
Vancouver, BC, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Peptides Canada, a domestic supplier of research-grade peptide compounds, today highlighted continued growth in demand for metabolic research peptides, including [...]
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
07/09/2026
Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
07/09/2026
Data highlights The STEP Young phase 3 trial met its primary endpoint, demonstrating greater body mass index (BMI) reduction in children aged 6 to under 12 treated with once-weekly subcutaneous semaglutide compared with [...]
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
07/09/2026
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress [...]
Novo Nordisk A/S - share repurchase programme
07/09/2026
Bagsværd, Denmark, 07 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
07/09/2026
COPENHAGEN, Denmark, September 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Clariane annonce l’offre de 500 millions d’euros d’obligations senior en vue de refinancer une partie de son endettement existant
07/09/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
Clariane has launched a proposed offering of €500 million of senior notes to refinance part of its existing indebtedness
07/09/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
Teva Announces Launch of Offering of Senior Notes
07/09/2026
TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today its intention to issue senior notes through its special purpose finance [...]
Virbac : Déclaration d'actions et de droits de vote 07/2026
07/09/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 07/2026
07/09/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 08/2026
07/09/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]

Pages